GlassScriptPhysician profile
Heather L Hunter
NPI 1316694854
$2,428.49
in general payments reported to CMS, 2019-2025
23 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $955 · 2024: $891 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.08 | 2022-2025 | |
| Novo Nordisk INC | $426.40 | 2022-2025 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $255.88 | 2023-2025 | |
| Lilly USA, LLC | $199.72 | 2022-2024 | Mounjaro |
| Mylan Specialty L.P. | $185.02 | 2022-2024 | Yupelri |
| Dexcom, INC. | $114.44 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $92.33 | 2022-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $74.22 | 2024-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $73.46 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.77 | 2023-2024 | Ofev, Jardiance |
| Exact Sciences Corporation | $54.42 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $47.53 | 2022-2023 | |
| Corcept Therapeutics | $40.43 | 2022 | |
| Axsome Therapeutics, INC. | $33.34 | 2024-2025 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.39 | 2022-2023 | Xifaxan, Trulance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $23.00 | 2024 | Sherlock |
| Viatris Specialty LLC | $19.72 | 2025 | Yupelri |
| Eisai INC. | $19.27 | 2024 | |
| Neos Therapeutics, LP | $18.92 | 2024 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $16.19 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $15.39 | 2023 | Shingrix, Boostrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.36 | 2025 | Caplyta |
| Medtronic, INC. | $14.21 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.